Faster Entry Into the Clinic with the Australian Advantage
Australia lets biotechs start most early-phase trials without an IND, with study start-up in 5–6 weeks from final protocol to approval and R&D rebates of up to 43.5% on eligible spend. The resulting data is accepted by the TGA, FDA, EMA, and MHRA.
Local Support for Korean Sponsors
Korean biotechs work with a CRO that already operates in their market. With our Asia Hub in South Korea, sponsors have local support from the first conversation through first dosing in Australia and beyond.
Early Data Built for the Markets That Come Next
Avance Clinical’s in-house scientific and regulatory expertise shapes study design and global regulatory strategy from the start, so a first-in-human dataset is designed to support the submissions a program will need in North America, Europe, and Asia.
One Partner Across Every Region with GlobalReady
Through the GlobalReady program, biotechs work with a single CRO from first-in-human through later-phase, multi-country studies across Australia, Asia Pacific, North America, and Europe. This integrated approach is designed to maintain aligned teams and consistent data standards as a program grows.
Therapeutic Depth Across More Than 250 Indications
Experience in more than 250 indications, with specialties in oncology, CNS, and renal and cardiometabolic.
